Suppr超能文献

胰岛素样生长因子-I 可预测小儿造血干细胞移植后窦状隙阻塞综合征。

Insulin-like growth factor-I predicts sinusoidal obstruction syndrome following pediatric hematopoietic stem cell transplantation.

机构信息

Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

出版信息

Bone Marrow Transplant. 2021 May;56(5):1021-1030. doi: 10.1038/s41409-020-01127-3. Epub 2020 Nov 20.

Abstract

Sinusoidal obstruction syndrome (SOS) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT) initiated through damage of sinusoidal endothelium and inflammation. Insulin-like growth factor-l (IGF-l) maintains and repairs endothelium and intestinal mucosa. We hypothesized that low IGF-l levels may increase the risk of inflammatory complications, such as SOS, in HSCT-patients. We prospectively measured IGF-l concentrations in 121 pediatric patients before, during, and after allogeneic HSCT. Overall, IGF-l levels were significantly reduced compared with healthy sex- and age-matched children. IGF-I levels pre-HSCT and at day 0 were inversely associated with C-reactive protein levels, hyperbilirubinemia, and number of platelet transfusions within the first 21 days post-transplant. Low levels of IGF-I before conditioning and at day of transplant were associated with increased risk of SOS diagnosed by the modified Seattle criteria (pre-HSCT: OR = 1.7 (95% CI: 1.2-2.6, p = 0.01), and the pediatric EBMT criteria (pre-HSCT: 1.7 (1.2-2.5, p = 0.009) and day 0: 1.7 (1.3-2.5, p = 0.001)/SDS decrease in IGF-1). These data suggest that IGF-I is protective against cytotoxic damage and SOS, most likely through trophic effects on endothelial cells and anti-inflammatory properties, and may prove useful as a predictive biomarker of SOS.

摘要

窦状隙阻塞综合征(SOS)是造血干细胞移植(HSCT)的一种潜在致命并发症,由窦状内皮损伤和炎症引起。胰岛素样生长因子-1(IGF-1)可维持和修复内皮和肠黏膜。我们假设低 IGF-1 水平可能会增加 HSCT 患者发生炎症并发症(如 SOS)的风险。我们前瞻性地测量了 121 例儿科患者在接受异基因 HSCT 前后的 IGF-1 浓度。总体而言,与性别和年龄匹配的健康儿童相比,IGF-1 水平显著降低。HSCT 前和 0 天的 IGF-I 水平与 C 反应蛋白水平、高胆红素血症和移植后 21 天内血小板输注次数呈负相关。预处理前和移植当天 IGF-I 水平较低与改良西雅图标准(HSCT 前:OR=1.7(95%CI:1.2-2.6,p=0.01)和儿科 EBMT 标准(HSCT 前:1.7(1.2-2.5,p=0.009)和第 0 天:1.7(1.3-2.5,p=0.001)/IGF-1 SDS 下降)诊断的 SOS 风险增加相关。这些数据表明,IGF-1 可通过对内皮细胞的营养作用和抗炎特性发挥保护作用,防止细胞毒性损伤和 SOS,并且可能作为 SOS 的预测生物标志物证明有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验